External Quality Assessment for Genomics & Molecular Pathology
Why Choose Labquality's Genomics & Molecular Pathology EQA?
Our Genomics & Molecular Pathology EQA schemes help laboratories assess and improve the quality of variant detection, interpretation and reporting using clinically relevant sample materials. Developed with genomics experts, the programme combines clinically relevant materials, comprehensive assessment and efficient electronic reporting to support high-quality molecular oncology testing.
Clinically relevant sample materials
Assess laboratory performance using carefully selected FFPE sample materials that reflect real-world molecular oncology testing.
Designed for molecular oncology laboratories
Suitable for laboratories performing NGS-based cancer panel testing and other molecular methods for the detection and interpretation of somatic variants.
Comprehensive performance assessment
Assess the quality of variant detection, interpretation and reporting to identify opportunities for quality improvement.
Supports quality improvement and accreditation
Demonstrate the quality of your molecular testing and support continuous improvement and accreditation activities.
Developed with genomics experts
Designed in collaboration with experienced genomics and molecular pathology professionals to ensure scientific relevance and practical value.
Efficient online reporting
Submit results and access reports through LabScala, Labquality's secure electronic reporting platform designed for efficient EQA participation.
Why participate in EQA?
Participation helps laboratories:
-
assess laboratory performance using clinically relevant materials
-
evaluate variant detection, interpretation and reporting
-
identify opportunities for quality improvement
-
support accreditation and continuous quality management
-
benchmark performance against peer laboratories
Trusted expertise in external quality assessment
Built on Labquality's decades of experience in external quality assessment, the Genomics & Molecular Pathology programme combines scientific expertise with clinically relevant sample materials and practical electronic reporting to support reliable molecular diagnostics.
About the programme
Labquality's Genomics & Molecular Pathology EQA programme is designed for laboratories performing molecular oncology testing using next-generation sequencing (NGS), targeted cancer panels and other molecular methods for analysing somatic variants in cancer samples.
The programme currently includes four oncology-specific EQA schemes for FFPE-based cancer panel testing. The programme will continue to expand with new EQA schemes and pilot rounds, including schemes based on cfDNA sample materials, to support the evolving needs of molecular diagnostics laboratories.
Available EQA schemes
NGS in Clinical Oncology – Pan Cancer
FFPE-based cancer panel testing. Product number: 6810
April 2027
NGS in Clinical Oncology - Breast Cancer
FFPE-based cancer panel testing. Product number: 6811
May 2027
NGS in Clinical Oncology - Colon Cancer
FFPE-based cancer panel testing. Product number: 6812
June 2027
NGS in Clinical Oncology - Lung Cancer
FFPE-based cancer panel testing. Product number: 6813
June 2027